Sage Journals: Discover world-class research

Retricted access

Research article

First published 2003-10

Canadian and US Drug Approval Times and Safety Considerations

Nigel SB Rawson, Kenneth I Kaitin

Annals of Pharmacotherapy

Retricted access

Other

First published 2005-7

The Review of New Drug Applications in Japan: The Decline in Approval Times after the Introduction of an Internalized Review System

Shunsuke Ono, Chisato Yoshioka, Orie Asaka [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1994-4

Who Needs Faster Drug Approval Times in Canada: The Public or the Industry?

Joel Lexchin

International Journal of Social Determinants of Health and Health Services

Retricted access

Research article

First published 1996-06

Is there a U.S. Drug Lag? The Timing of New Pharmaceutical Approvals in the G-7 Countries and Switzerland

Stuart O. Schweitzer, Maurice E. Schweitzer, Marie-Jo Sourty-Le Guellec

Medical Care Research and Review

Retricted access

Research article

First published 1996-4

An Analysis of Regulatory Review Times of Supplemental Indications for Already-Approved Drugs: 1989-1994

Joseph A. DiMasi, Jeffrey S. Brown, Louis Lasagna

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 2009-3

Factors Associated with Multiple FDA Review Cycles and Approval Phase Times

Joseph A. DiMasi, Laura Faden

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2018-11

Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan

Keiji Nishiyama, Satoshi Toyoshima, Hiroaki Yamada [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 1995-1

The Timeliness of New Drug Approvals in Canada

Nigel S. B. Rawson

International Journal of Social Determinants of Health and Health Services

Retricted access

Other

First published 2000-7

Measuring the Pace of New Drug Development in the User Fee ERA

Kenneth I. Kaitin, Joseph A. DiMasi

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 2008-1

Assessing the Performance of the EMEA's Centralized Procedure: A Comparative Analysis with the US FDA

Laura B. Faden, Kenneth I. Kaitin

Therapeutic Innovation & Regulatory Science

Search results